Abstract Personalized medicine has the promise to tailor medical care based on the patient's genetic make-up and clinical variables such as gender, race, and exposure to environmental stimuli. Recent progress in pharmacogenetic and pharmacogenomic studies has suggested that drug response to therapeutic treatments is likely a complex trait influenced by a variety of genetic and non-genetic factors. Identifying molecular targets (e.g., genetic variants) delineating the genetic basis of drug response could help understand the complex nature of drug response. The last decade has witnessed significant advances in genome-wide profiling technologies for genetic/epigenetic variations and gene expression. As an unbiased, cell-based model for pharmacogenomic discovery, a tremendous resource of whole-genome molecular targets has been accumulated for the HapMap lymphoblastoid cell lines (LCLs). The current progress, particularly in cancer pharmacogenomics, using the LCL model is reviewed to illustrate the potential impact of systems biology approaches on pharmacogenomic discovery.
Introduction
Personalized medicine provides the promise of health care tailored to an individual patient's genetic make-up and/or other clinical information such as gender, race, age, and exposure to environmental stimuli. The inter-individual variation in drug response has been an important clinical observation that may influence the efficacy of a therapeutic intervention in patients. Individual response to a medication could range from beneficial outcomes to adverse side effects and even fatal complications. Of particular concern are drugs that have a narrow therapeutic index, i.e., a small range of doses at which a medication may provide therapeutic benefits without causing severe adverse effects or complications. Warfarin, an anticoagulant normally prescribed for preventing thrombosis and thromboembolism, presents an example of how the patients' variation in drug response may require personalized decisions for clinical management [1] . In order to optimize its therapeutic efficacy without risking severe complications including bleeding, personalized dosing and close monitoring are required to achieve ideal clinical outcome of warfarin treatment. Recent pharmacogenetic and pharmacogenomic studies have indicated the associations of single nucleotide polymorphisms (SNPs) in CYP2C9 (encoding cytochrome P450, family 2, subfamily C, polypeptide 9) and VKORC1 (encoding vitamin K epoxide reductase complex, subunit 1) with warfarin dosing requirements [2] . The warfarin example demonstrated the importance of understanding the genetic basis of drug response, and the potential applications of pharmacogenomic approaches in achieving optimal outcomes from therapeutic treatments in patients.
Given that the inter-individual response to a medication could be influenced by genes involved in both pharmacokinetics and pharmacodynamics, as well as by environmental factors such as food intake (e.g., irinotecan's interaction with St. John's wort) [3] , drug response is likely to be a complex trait or phenotype affected by multiple genetic, epigenetic, and non-genetic factors. Elucidating the molecular targets (e.g., gene expression, SNPs, microRNAs, CpG methylation) associated with the variability of drug response could therefore enhance our understanding of the genetic/epigenetic basis of drug response, as well as provide potential intervention targets or diagnostic/prognostic biomarkers for achieving optimal therapeutic outcomes. In terms of experimental approaches, the last decade has witnessed significant advances in genome-wide profiling technologies (e.g., microarray and the next-generation sequencing), thus opening up the possibilities for high-throughput profiling and measuring of various molecular targets including gene expression, genetic variations, and, more recently, epigenetic variations. In the meantime, the launch of the Human Genome Project and other parallel large-scale projects such as the International HapMap Project [4, 5] and The 1000 Genomes Project [6, 7] has promoted an unprecedented improvement of our understanding of the human genetic variation from diverse global populations. Pharmacogenetic and pharmacogenomic studies have benefited from these technical advancements and scientific breakthroughs during the past decade. In this review, the progress in identifying genome-wide molecular targets for the aims of delineating the genetic basis of drug response will be summarized using the HapMap [4, 5] lymphoblastoid cell lines (LCLs), a whole-genome, cell-based model, as an example, particularly with an emphasis from a systems biology perspective.
Cell-Based Pharmacogenomics Model
The HapMap LCLs were derived from apparently healthy individuals of major continental populations [4, 5] . The latest phase 3 HapMap samples are comprised of [1,100 samples from 11 global populations including major Asian, European, and African ethnic groups [8] . A comprehensive resource of gene expression and genetic variation data has been accumulated on the HapMap samples, particularly the CEU (Caucasian residents from Utah, USA) and YRI (Yoruba people from Ibadan, Nigeria) samples ( Table 1) . The availability of cell cultures for these LCLs from the Coriell Institute for Medical Research (Camden, NJ, USA) has allowed phenotying in these samples, including drug response and transcriptomic profiling, facilitating pharmacogenomic discovery based on this model. In particular, the HapMap LCL samples have been used for modeling cytotoxicities induced by chemotherapeutic agents and response to radiation [9, 10] , for which normal controls often cannot be found, given the toxicities of these treatments.
This cell-based model benefits from the availability of comprehensive genetic variation data including genotypes of [4 million SNPs for phase 1/2 [11] and [1.6 million SNPs for phase 3 samples [8] from the HapMap Project [4, 5] . The 1000 Genomes Project [6, 7] also covers a subset of the HapMap samples, thus providing even more dense coverage of genetic variants ([17 million SNPs), potentially useful for genotype imputation [12] to expand the original HapMap data. Given the fundamental role of gene expression in determining cellular phenotypes, microarray platforms including the Illumina BeadChip [13] (*45,000 transcripts), the Affymetrix Human Focused Array [14] (*9,000 genes), and the Affymetrix Human Exon Array [15, 16] (*22,000 transcript clusters and 1.4 million exons), and transcriptome sequencing (RNA-Seq) [17] were used to profile whole-genome gene expression in the HapMap samples to investigate the genetic architecture of gene expression variation both within and between human populations. Notably, eQTLs (expression quantitative trait loci), which are local (cis-acting) or distant (trans-acting) SNPs associated with quantitative gene expression phenotypes, derived from the HapMap samples [18] were demonstrated to be an important feature enriched among GWAS (genome-wide association study) loci associated with complex traits [19, 20 • In particular, etoposide (VP-16) represents the first chemotherapeutic agent studied for pharmacogenomic loci using the HapMap LCL model [29] . Etoposide is an anticancer drug, which belongs to the class of topoisomerase II inhibitors [30] . Common adverse effects include, for example, myelosuppression and gastrointestinal toxicity, as well as risk of cardiac toxicity and secondary leukaemia [31] . Identifying genetic variants and gene expression phenotypes associated with etoposide-induced cytotoxicity can therefore enhance our understanding of the genetic basis of this cellular phenotype.
In this pioneer study, a genetics-driven 'triangle' approach ( Fig. 1 ) was utilized to identify eQTLs that may contribute to etoposide-induced cytotoxicity. The study design aimed to integrate three genomic association tests, i.e., SNPs versus cytotoxicity, SNPs versus gene expression, and gene expression versus cytotoxicity. Specifically, common SNPs from the HapMap Project were evaluated for associations with etoposide-induced cytotoxicity (represented by IC 50 , concentration at which 50 % of cell growth is inhibited), which was measured in 176 HapMap CEU and YRI samples. These cytotoxicityassociated SNPs (P \ 1E-4) were then evaluated for associations with gene expression phenotypes, which were profiled using the Affymetrix Human Exon 1.0ST array (covering *22,000 gene-level transcript clusters) ( Table 1 ). The significant gene expression phenotypes were finally rechecked for associations with etoposide-induced cytotoxicity. With this unbiased, step-wise, genetics-driven strategy, pharmacogenomic loci for etoposide-induced cytotoxicity were prioritized based on their potential regulatory functions for those genes associated with drug response. The final findings implicated several cancer-related genes including AGPAT2 (encoding 1-acylglycerol-3-phosphate O-acyltransferase 2), IL1B (encoding interleukin 1, beta), and WNT5B (encoding wingless-type MMTV integration site family, member 5B), as well as some genes not yet known to be associated with sensitivity to etoposide [29] (i.e., novel candidate genes).
Genetic Mapping of Drug Response: CNVs
Common CNVs have been demonstrated to partially contribute to natural gene expression variation using the HapMap LCL model [13] . For example, SNPs and CNVs were shown to capture 83.6 and 17.7 % of the total detected genetic variation in gene expression profiled using the Illumina platform, respectively; however, the signals from the two types of variation had little overlap [13] . Previous studies also implicated CNVs in a variety of complex disorders such as rheumatoid arthritis, Crohn's disease, type 1 diabetes, and type 2 diabetes [32] . In addition, a comprehensive scan of the NHGRI GWAS Catalog [19] showed an overrepresentation of SNPs tagging CNVs relative to frequency-matched SNPs [33] , suggesting the potential roles of CNVs in determining complex traits and phenotypes. Expanding pharmacogenomic discovery to include CNVs could therefore provide novel insights into the genetic basis for drug response, beyond SNPs.
Recently, a comprehensive genome-wide study of [5,000 common CNVs [34] 50 . Therefore, extensive CNV regions associated with cellular sensitivities were identified for functionally diverse chemotherapeutics, supporting the hypothesis that CNVs contribute to variation in drug response. Importantly, although SNPs tag some of the CNVs associated with drug sensitivities, several of the most significant CNV-drug associations were demonstrated to be independent of SNPs. Consequently, CNVs represent an independent source of genetic variations for pharmacologic phenotypes, in addition to SNPs.
Epigenetics of Drug Response: MicroRNAs
MicroRNAs (miRNAs) are short, non-coding RNA molecules that represent a class of gene regulators that generally downregulate gene expression at the post-transcriptional level, i.e., through translational repression and mRNA degradation by binding to the 3 0 untranslated regions (3 0 UTRs) of the target mRNA [36] . Experimental evidence has been accumulated for the roles of miRNAs in regulating pharmacology-related genes and drug responses. For example, miRNAs have been shown to regulate or correlate with several VIPs (very important pharmacogenes) [e.g., miR-146a and BRCA1 (encoding breast cancer 1, early onset), miR-126* and CYP2A6 (encoding cytochrome P450, family 2, subfamily A, polypeptide 6)] [37, 38] maintained by the PharmGKB database [39] . Given the critical roles of miRNAs for various diseases (e.g., cancer, cardiovascular diseases) [40] [41] [42] [43] , incorporation of miRNAs into pharmacogenomic discovery could provide improved insights into drug response phenotypes [44] . In particular, whole-genome miRNA expression levels (covering *1,000 human miRNAs using the Exiqon miRCURY LNA platform) are now available for the HapMap CEU and YRI samples [22, 45] , allowing further integrative analyses of miRNAs in pharmacogenomic discovery.
For example, taking advantage of the miRNA expression data in the 60 unrelated CEU samples (Table 1) , miR193b* and miR-320 were shown to inhibit the expression of five previously identified platinating agent-associated genes: CRIM1 (encoding cysteine rich transmembrane BMP regulator 1), IFIT2 (encoding interferon-induced Fig. 1 Integration of genome-wide molecular profiles in pharmacogenomic discovery. A genetics-driven 'triangle' approach aims to prioritize genetic variants associated with drug response by integrating information from gene expression and genetic variation. Expanding pharmacogenomic discovery to incorporate other gene regulatory mechanisms, e.g., epigenetic mechanisms such as microRNAs and DNA methylation is critical for elucidating the complex nature of drug response. Genetic variants associated with drug response can belong to various functional classes. SNP single nucleotide polymorphism, CNV copy number variant, GWAS genome-wide association study, eQTL expression quantitative trait locus, miRSNP SNP associated with microRNA expression, M-eQTL eQTL through regulating DNA methylation protein with tetratricopeptide repeats 2), OAS1 (encoding 2 0 -5 0 -oligoadenylate synthetase 1, 40/46 kDa), KCNMA1 (encoding potassium large conductance calcium-activated channel, subfamily M, alpha member 1), and GRAMD1B (encoding GRAM domain containing 1B) [46 •• ] . Furthermore, by integrating miRNAs with genetic variation and gene expression using the HapMap model, this pharmacogenomic study highlighted a potential mechanism of action for a previously observed genotype-survival outcome association in a cohort of ovarian cancer patients [46 •• ] , indicating the relevance of pharmacogenomic findings based on this model to clinical observations.
Epigenetics of Drug Response: DNA Methylation
DNA methylation, currently the most studied epigenetic mechanism, has been demonstrated to be an important class of gene regulators that putatively reflect the influence from environmental factors. Given the critical role played by DNA methylation in gene regulation, incorporation of epigenomic profiling would substantially add to the knowledge of how genetics, epigenetics, and environmental factors may contribute to gene expression and pharmacogenomics at a new level of complexity [47] . A high-throughput microarray platform (Illumina 27 K array, covering *27,000 promoter CpGs) has been used to investigate DNA methylation variation in promoter regions in the CEU [24, 25] and YRI [24] samples. More recently, a much more comprehensive dataset (Table 1) , using the Illumina 450 K array and covering more than 450,000 CpGs across the human genome [48] , has been generated for the HapMap CEU and YRI samples [23, 49] , thus allowing epigenomic mapping in pharmacogenomic discovery to incorporate this important gene regulatory mechanism.
The potential impact of integrating epigenomic mapping of CpG methylation in pharmacogenomic discovery can be demonstrated by a recent study on clofarabine [50 •• ], a purine nucleoside analog, which is used in the treatment of refractory or relapsed acute leukemia and as induction therapy for stem cell transplantation [51] [52] [53] . Particularly, a GWAS using the HapMap genotypic data was performed to identify 182 SNPs associated with clofarabine cytotoxicity in the HapMap CEU and YRI samples [50 •• ] . By integrating SNPs, gene expression, and DNA methylation data on these samples (Table 1) , a set of 3 SNPs and 3 CpG sites targeting genes, including SETBP1 (encoding SET binding protein 1), BAG3 (encoding BCL2-associated athanogene 3), and KLHL6 (encoding kelch-like family member 6), were found to explain 43.1 % of the observed variation in clofarabine-induced cytostoxicities, therefore indicating that incorporating these epigenetic profiles could help account for more of the observed variation in this drug response phenotype, compared to the SNPs alone (43.1 vs. 29.8 %) [50 •• ] .
Conclusion
During the past decade, technical advances in highthroughput profiling platforms, particularly microarrays, have allowed genome-wide profiling of various molecular targets including gene expression, SNP genotypes, copy number polymorphisms, microRNAs, and DNA methylation, thus facilitating pharmacogenomic studies that aim to identify genetic and epigenetic determinants associated with drug response. The HapMap LCL samples represent an example of how investigators have taken advantage of the technical advances in order to incorporate a variety of molecular targets into pharmacogenomic discovery. Though with some limitations (e.g., LCLs only represent one tissue type) [54] , by using this unbiased, cell-based model, significant progress has been made to elucidate genetic and epigenetic contributions to cytotoxicities induced by anticancer chemotherapeutic agents of different mechanisms. With the next-generation sequencing technologies expected to become more accessible in the near future, a much more comprehensive genome-wide coverage of various molecular targets, including, for example, other novel gene regulatory mechanisms such as histone modifications, will allow the application of systems biology approaches to further expand the current pharmacogenomic discoveries to enhance our understanding of the complex genetic basis of drug response, ultimately facilitating the realization of personalized medical care.
